LPA

There are 172 papers on LPA in aging research: 13 trials and 86 observational studies in people, 2 in animals, 64 reviews. The newest story, Nov 7, 2026: “Blood particle linked to differing artery disease risks”.

Gene

172 papers study it25 findings

HGNCNCBI GeneTaxon

17 new papers in 30 daysSee all 172 papers on LPA

At a glance

The findings reach people, from one lab or study. 13 independent labs in 9 countries; 28 trials, 5 with no results posted.

“rs3798220-C carrier status was associated with increased MACE risk in the placebo group (HR: 1.90; 95% CI: 1.11-3.24)”
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) GenotypesJournal of the American College of Cardiology2022doi:10.1016/j.jacc.2022.07.027

1 of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 13 independent labs in 9 countries
  • 1 finding against
  • 28 trials, 5 with no results posted
  • Funders: National Heart, Lung, and Blood Institute and others
  • 10 of 21 findings with company ties
  • 28 of 28 trials sponsored by developers of drugs aimed at it
  • Human trial13
  • Humans86
  • Animals2
  • In silico4

Effects

11

Maternal fertility and pregnancy outcomes

no changein humans1

1 study
  1. LPA was not clearly linked with maternal fertility and pregnancy outcomes in humans (Complete LPA deficiency due to homozygous loss-of-function variants).

    “complete lifelong LPA deficiency due to high-confidence LPA loss-of-function variants is not associated with overt adverse maternal fertility, pregnancy or child health outcomes.”

    HumansComplete LPA deficiency due to homozygous loss-of-function variantslifelongfemalesn = 19

    Analysis of reproductive traits associated with lipoprotein(a) deficiency in participants from the Pakistan Genome Resource

    bioRxivPreprint

Fertility-related traits

no changein humans1

1 study
  1. LPA was not clearly linked with fertility-related traits in humans (Carriers of LPA loss-of-function variants; additive and recessive models).

    “LPA LoF associations with fertility-related traits (ever having a child and number of children) under additive and recessive models”

    HumansCarriers of LPA loss-of-function variants; additive and recessive models

    Analysis of reproductive traits associated with lipoprotein(a) deficiency in participants from the Pakistan Genome Resource

    bioRxivPreprint

Prostate cancer incidence

no changein humans1

1 study
  1. LPA showed no clear effect on prostate cancer incidence in humans (LPAL2-LPA variants, after correction for multiple testing).

    “The genetic cohort study found no robust association between LPAL2-LPA variants and prostate cancer incidence after correction for multiple testing.”

    ReviewLPAL2-LPA variants, after correction for multiple testing

    Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence

    International journal of molecular sciences

Platelet

upin mice1

1 study
  1. LPA increases platelet in mice (laser-induced mesenteric vessel injury).

    “apo(a) increased platelet and fibrin volumes in the thrombi without affecting fibrinolysis.”

    Animalslaser-induced mesenteric vessel injurymesenteric vessel

    Lipoprotein(a) promotes thrombosis through platelet activation and promotion of a lysis-resistant thrombus architecture

    bioRxivPreprint

Glycemic biomarkers

no changein humans1

1 study
  1. LPA was not clearly linked with glycemic biomarkers in humans (comparison by rs41272114 genotype).

    “Mean levels of glycemic biomarkers also did not differ by rs41272114 genotype.”

    Humanscomparison by rs41272114 genotype

    Genetically determined very low lipoprotein(a) is not associated with type 2 diabetes and glycemic traits

    American journal of preventive cardiology

More on Glycemic biomarkers

Type 2 diabetes

no changein humans1OR 0.97

1 study
  1. LPA was not clearly linked with type 2 diabetes in humans (LPA rs41272114 CT or TT genotype compared with CC) (CT vs CC: OR 0.97, 95% CI 0.94–1.00; TT vs CC: OR 1.01, 95% CI 0.89–1.15).

    “We did not observe increased odds of type 2 diabetes by rs412722114 genotype”

    HumansLPA rs41272114 CT or TT genotype compared with CCn = 519,892

    Genetically determined very low lipoprotein(a) is not associated with type 2 diabetes and glycemic traits

    American journal of preventive cardiology

More on Type 2 diabetes

Carotid intima-media thickness

no changein humans1

1 study
  1. LPA was not clearly linked with carotid intima-media thickness in thyroid dysfunction.

    “No significant association was found between Lp(a) and cIMT.”

    Humansin thyroid dysfunctionn = 54

    Correlation of triglyceride-glucose index, complement C5, and lipoprotein(a) with carotid intima-media thickness in thyroid dysfunction: A cross-sectional study

    Endocrine regulations

More on Carotid intima-media thickness

Atherosclerotic cardiovascular disease

no changein humans1OR 0.97

1 study
  1. LPA was not clearly linked with atherosclerotic cardiovascular disease in humans (rare predicted loss-of-function variants) (OR 0.97).

    “rare LPA variants alone showed no significant association with ASCVD (OR, 0.97; p = 0.67)”

    Humansrare predicted loss-of-function variants

    Genetic Evidence Suggests Combined Inhibition of Lipoprotein(a) and PCSK9 to Lower Atherosclerotic Cardiovascular Disease Risk.

    AHA Scientific Sessions 2025 abstract

More on Atherosclerotic cardiovascular disease

Aging-GIP1

downin humans1

1 study
  1. LPA is linked with lower aging-GIP1 in humans.

    “we provide robust evidence for a detrimental effect of blood levels of apolipoprotein(a) and vascular cell adhesion molecule 1 on aging-GIP1”

    Humansproteome-wide two-sample Mendelian randomization and colocalization of blood apolipoprotein(a) levels

    Mendelian randomization of genetically independent aging phenotypes identifies LPA and VCAM1 as biological targets for human aging

    Nature aging

GIP1

downin humans1

1 study
  1. LPA is linked with lower GIP1 in humans.

    “we provide robust evidence for a detrimental effect of blood levels of apolipoprotein(a) (LPA) and vascular cell adhesion molecule 1 (VCAM1) on GIP1”

    Humansblood

    Genetically independent phenotype analysis identifies LPA and VCAM1 as drug targets for human ageing

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

All 11

Associations

12

Lipoprotein

downin humans1upin silico1

2 studies
  1. LPA is associated with lipoprotein in humans (p < 0.0001).

    “the greater the apo(a) molecular weight, the lower the Lp(a) level (p < 0.0001)”

    Humansn = 100

    Low density lipoprotein cholesterol, lipoprotein(a), and apo(a) isoforms in the elderly: relationship to fasting insulin. Associazione Medica Sabin

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  2. LPA predicts lipoprotein in silico (r2 0.46 (95% CrI 0.32 to 0.6)).

    “Overall r2 of the haplotype model was 0.46 (95% Credible Interval [CrI] 0.32 to 0.6), with similar performance across genetically inferred ancestries and cohorts.”

    In silico

    Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations

    medRxiv : the preprint server for health sciencesPreprint

More on Lipoprotein

Major adverse cardiovascular events

upin humans1HR 1.9

1 study
  1. LPA raises the risk of major adverse cardiovascular events in humans (rs3798220-C carriers, placebo arm) (HR 1.90; 95% CI 1.11-3.24).

    “rs3798220-C carrier status was associated with increased MACE risk in the placebo group (HR: 1.90; 95% CI: 1.11-3.24)”

    Human trialrs3798220-C carriers, placebo arm

    Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

    Journal of the American College of Cardiology

  2. LPA raises the risk of major adverse cardiovascular events in humans (placebo arm) (HR: 1.90; 95% CI: 1.11-3.24).

    “In the placebo arm of the trial, rs3798220-C carrier status was associated with increased MACE risk (HR: 1.90; 95% CI: 1.11-3.24; P = 0.018).”

    Human trialplacebo armmedian follow-up of 4.7 yearsn = 406

    Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

    Journal of the American College of Cardiology

More on Major adverse cardiovascular events

Carotid atherosclerotic plaques

mixedin humans1

1 study
  1. LPA is associated with carotid atherosclerotic plaques in humans (Bayesian colocalization within 1 Mb shared with aortic valve calcification) (PP.H4 = 0.99).

    “and between AVC and carotid plaque (PP.H4 = 0.99)”

    HumansBayesian colocalization within 1 Mb shared with aortic valve calcificationcarotid artery

    Gene region linked to valve calcium and artery plaque

    ESC Congress 2026 abstract

More on Carotid atherosclerotic plaques

Coronary artery calcification

mixedin humans1

1 study
  1. LPA is associated with coronary artery calcification in humans (Bayesian colocalization within 1 Mb shared with aortic valve calcification) (PP.H4 = 0.99).

    “Bayesian colocalization analysis within 1 Mb supported a shared causal signal at the LPA locus between AVC and CAC”

    HumansBayesian colocalization within 1 Mb shared with aortic valve calcificationcoronary artery

    Gene region linked to valve calcium and artery plaque

    ESC Congress 2026 abstract

More on Coronary artery calcification

Aortic valve calcification

mixedin humans1

1 study
  1. LPA is associated with aortic valve calcification in humans (GWAS of CT-derived AVC in SCAPIS) (p-value = 3.6 x 10-31).

    “The AVC GWAS identified a strong association signal at the LPA locus (lead variant rs118039278, p-value = 3.6 x 10-31).”

    HumansGWAS of CT-derived AVC in SCAPISaortic valven = 24,303

    Gene region linked to valve calcium and artery plaque

    ESC Congress 2026 abstract

More on Aortic valve calcification

Calcific aortic valve disease

upin humans1

1 study
  1. LPA is associated with calcific aortic valve disease in humans.

    “genetic studies consistently link it with lipoprotein little (a) [Lp(a)]”

    Review

    Lipids and lipoproteins in calcific aortic valve disease

    Current opinion in lipidology

More on Calcific aortic valve disease

Calcific aortic valve stenosis

upin humans1

1 study
  1. LPA raises the risk of calcific aortic valve stenosis in humans (genetic and Mendelian randomization evidence).

    “Genetic and Mendelian randomization studies support a likely causal contribution of the LPA locus and lifelong exposure to apoB-containing lipoproteins to aortic valve calcification and incident CAVS.”

    Reviewgenetic and Mendelian randomization evidence

    Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target

    Frontiers in medicine

More on Calcific aortic valve stenosis

Coronary artery disease

downin silico1OR 0.68

1 study
  1. LPA lowers the risk of coronary artery disease in silico (per 50 mg/dL reduction in Lp(a) levels) (OR 0.68, 95% CI 0.65-0.71).

    “Genetically predicted lower Lp(a) was associated with reduced risks of CHD [odds ratio (OR) per 50 mg/dL reduction in Lp(a) levels, 0.68; 95% confidence interval (CI), 0.65-0.71]”

    In silicoper 50 mg/dL reduction in Lp(a) levelsn = 408,687

    Genetic variants lowering lipoprotein(a) and downregulating interleukin-6 signalling are additively associated with a decreased risk of cardiovascular disease

    European journal of preventive cardiology

More on Coronary artery disease

Atherosclerotic cardiovascular disease

downin humans1

1 study
  1. LPA is linked with a lower risk of atherosclerotic cardiovascular disease in humans (common cis-pQTL instruments).

    “lower genetically proxied LPA, PCSK9, or both were associated with significantly reduced ASCVD odds”

    Humanscommon cis-pQTL instruments

    Genetic Evidence Suggests Combined Inhibition of Lipoprotein(a) and PCSK9 to Lower Atherosclerotic Cardiovascular Disease Risk.

    AHA Scientific Sessions 2025 abstract

More on Atherosclerotic cardiovascular disease

Age-related macular degeneration

upin humans1

1 study
  1. LPA is associated with age-related macular degeneration in humans (P = 0.007).

    “LPA was identified (P = 0.007) as a novel SNP associated with increased AMD risk.”

    Humans

    High-Density Lipoproteins Associated with Age-Related Macular Degeneration in the All of Us Research Program

    Ophthalmology

More on Age-related macular degeneration

All 12

Latest

Dec 2025: 0Jan 2026: 14Feb 2026: 19Mar 2026: 19Apr 2026: 1May 2026: 2Jun 2026: 5Jul 2026: 11Aug 2026: 17Sep 2026: 13Oct 2026: 7Nov 2026: 12120 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Blood particle linked to differing artery disease risks

For every 50 mg/dL higher mass concentration, relative risk was 18% higher for peripheral artery disease and 17% higher for coronary disease.For every 50 mg/dL higher mass concentration, relative risk was 18% higher for peripheral artery disease and 17% higher for coronary disease.

Cohort · 2,549 peopleBiomarkers
AHA Scientific Sessions 2026 Abstract

Genetic analysis links a blood fat particle to 60 proteins

Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or…Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or heart-valve narrowing.

Mendelian randomization · 28,949 peopleMechanisms

See all 172 papers on LPA